I’ve talked about video game spin-offs that have ended up as pretty much forgotten a few times on the channel in the past. But what about spin-offs that have managed to outshine their main series, and ...

I spent a few nights with the Akaso Sight-300 and came away fairly impressed. My previous experiences with night vision have ...

Taylor Swift’s highly anticipated 12th studio album and Matthew McConaughey in "The Lost Bus" are some of the new television, ...

The Tulsa area power provider, Public Service Company of Oklahoma, has new technology to deploy for the next winter weather storm, and practiced using it during a drill on Wednesday. PSO utilizes ...

Thanks to its relationship with Amazon, this budget scope has become a best-seller for the millions of shooters looking for a ...

Clym reports small businesses must adapt to comply with data privacy laws or face risks like fines, lawsuits, and lost customer trust.

Maker of Doritos, Pepsi, and Quaker oats reveals first ESG update since confirming it has delayed its net zero goal by a decade PepsiCo reduced its Scope 1 and 2 greenhouse gas emissions by 18 per ...

With various scopes, stocks, and suppressors to suit your playstyle and aesthetic preferences. Here's a look at the Active Matter weapon attachments!

The Rated Red Crew sights in a scope in three steps. Charlie Kirk shooting suspect Tyler Robinson arrested, widow vows to fight Jon Cryer Says ‘I Got a Third' of Charlie Sheen's Pay on ‘Two and a Half ...

Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent ...

Value is value, no matter where -- or how -- you find it. And that's what we'll aim to do each week in this space -- finding value. Ben Solak and Seth Walder bring different perspectives into how they ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...